Lobbying client
KEDRION BIOPHARMA
Production of Plasma-Derived Therapies
Filings
7
Filed by
1
Reported in-house
—
Reported by firms
$820,000
Reported lobbying by year
The larger of in-house and firm-reported each year, $ thousands
2025 to 2026
Filings
7 filings, newest first.
| Filing | Filed by | Amount |
|---|---|---|
|
3rd Quarter - Report 3rd Quarter 2026
|
PRIME POLICY GROUP | $200,000 reported |
|
2nd Quarter - Report 2nd Quarter 2026
|
PRIME POLICY GROUP | — reported |
|
1st Quarter - Report 1st Quarter 2026
|
PRIME POLICY GROUP | $140,000 reported |
|
4th Quarter - Report 4th Quarter 2025
|
PRIME POLICY GROUP | $140,000 reported |
|
3rd Quarter - Report 3rd Quarter 2025
|
PRIME POLICY GROUP | $170,000 reported |
|
2nd Quarter - Report 2nd Quarter 2025
|
PRIME POLICY GROUP | $170,000 reported |
|
Registration 2nd Quarter 2025
|
PRIME POLICY GROUP | — reported |
Filed by
Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.
| Firm | Reports | Amount |
|---|---|---|
| PRIME POLICY GROUP | 6 | $820,000 |
Issues lobbied
How many report sections named each issue, counting the current version of each report.
| Issue | Code | Mentions |
|---|---|---|
| Trade (domestic/foreign) | TRD | 7 |
From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.